Asia Spotlight: Innovative, Differentiated Generics To Lead Merck Into Emerging Markets, Says EM President Kevin Ali
Executive Summary
MUMBAI – Merck & Co. President for Emerging Markets Kevin Ali likes to understand the “ground feel” of a company, says a senior company executive at its India affiliate MSD, and that need to see things in person may have brought the busy executive trotting back to India in less than three months of signing a “transformative deal” with Sun Pharmaceutical Industries Ltd.
You may also be interested in...
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
Merck Invests In China Oncology Start-up BeiGene
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11